Logo
x

Search

Subscribe Now

cancer

AbbVie to Acquire ImmunoGen for $10.1B

AbbVie to Acquire ImmunoGen for $10.1B

  • December 1, 2023
Biosimilar Solutions Reports the Initiation of Registrational Clinical Trials for Biosimilar BSC0826 to Treat Cancer

Biosimilar Solutions Reports the Initiation of Registrational Clinical Trials for Biosimilar BSC0826 to Treat Cancer

  • April 13, 2022
Regeneron Entered into a License Agreement with Nykode to Develop Vaccines Against Cancer and Infectious Diseases

Regeneron Entered into a License Agreement with Nykode to Develop Vaccines Against Cancer and Infectious Diseases

  • November 23, 2021
CStone Signs an Exclusive License Agreement with Jiangsu Hengrui to Develop and Commercialize CS1002 in Greater China

CStone Signs an Exclusive License Agreement with Jiangsu Hengrui to Develop and Commercialize CS1002 in Greater China

  • November 22, 2021
Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China

  • October 28, 2021
Genentech Signs a License Agreement with Adaptimmune to Develop and Commercialize Cancer-Targeted Allogeneic T-cell Therapies

Genentech Signs a License Agreement with Adaptimmune to Develop and Commercialize Cancer-Targeted Allogeneic T-cell Therapies

  • September 8, 2021
ELIAS Animal Health Reports USDA’s Full Approval of ELIAS Cancer Immunotherapy (ECI) for Canine Osteosarcoma

    ELIAS Animal Health Reports USDA’s Full Approval of ELIAS Cancer Immunotherapy (ECI) for Canine Osteosarcoma

    • March 20, 2025
    Oxford BioTherapeutics and Roche Collaborate to Discover Next-Gen Biologics for Cancer Treatment

      Oxford BioTherapeutics and Roche Collaborate to Discover Next-Gen Biologics for Cancer Treatment

      • March 20, 2025
      Innovent and HUTCHMED Report P-II/III (FRUSICA-2) Trial Data of Sintilimab + Fruquintinib for Metastatic Renal Cell Carcinoma (RCC)

        Innovent and HUTCHMED Report P-II/III (FRUSICA-2) Trial Data of Sintilimab + Fruquintinib for Metastatic Renal Cell Carcinoma (RCC...

        • March 19, 2025
        Bridging the Gap Between Conventional and Integrative Medicine

          Bridging the Gap Between Conventional and Integrative Medicine

          • March 18, 2025
          China’s NMPA Accepts BLA of Zai Lab’s Tivdak for Recurrent or Metastatic Cervical Cancer

            China’s NMPA Accepts BLA of Zai Lab’s Tivdak for Recurrent or Metastatic Cervical Cancer

            • March 13, 2025
            Arvinas & Pfizer Reports Topline Data from P-III (VERITAC-2) Trial of Vepdegestrant for Breast Cancer

              Arvinas & Pfizer Reports Topline Data from P-III (VERITAC-2) Trial of Vepdegestrant for Breast Cancer

              • March 12, 2025
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.